IECURE, INC.
🇺🇸United States
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
Recruiting
- Conditions
- Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseUrea Cycle Disorders, Inborn
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- iECURE, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT06805695
- Locations
- 🇬🇧
Great Ormond Street Hospital, London, United Kingdom
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Phase 1
Recruiting
- Conditions
- Ornithine Carbamoyltransferase Deficiency (Disorder)Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseUrea Cycle Disorders, Inborn
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- iECURE, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06255782
- Locations
- 🇺🇸
UCLA Mattel Children's Hospital, Los Angeles, California, United States
🇺🇸Children's Hospital of Colorado, Anshutz Medical Campus, Aurora, Colorado, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
News
No news found